Mirati – which is expecting a verdict on adagrasib from the FDA in December - also said the disease control rate was 80% with adagrasib, while the median duration of response came in at 8.5 ...
Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...
Hosted on MSN10mon
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain MutationMirati Therapeutics Inc., a Bristol Myers Squibb company, funded this study. Last week, Bristol Myers announced results from the Phase 3 KRYSTAL-12 study, evaluating Krazati (adagrasib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback